Redeye leaves a comment on Idogen following today's news that the company announced a rights issue of SEK 50m and that it has submitted its application to start its phase l/lla-trial with IDO 8, expected to commence in Q2 2022. We adjust our fair value range for the dilution.
LÄS MER